Research and Markets: Pharmaceutical Distribution in the US: Current and Future Perspectives - Wholesale Sector Consolidat

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/ab0ae1/pharmaceutical_dis) has announced the addition of the "Pharmaceutical Distribution in the US: Current and Future Perspectives" report to their offering.

Comprehensive overview of the business of pharmaceutical distribution in the US. Full analysis of the challenges facing the sector, plus 17 case studies.

In the US, the pharmaceutical supply chain involves the daily delivery of approximately 13 million prescription products to pharmacies, hospitals, clinics and other healthcare provider locations.

In recent years, the US government and interested parties have made increasing efforts to protect the national supply chain for medicines distribution. Since it represents the means for medicines to reach patients, any breaches in the system would be catastrophic and could affect millions of people. The system faces numerous external threats, including counterfeiting, terrorism and disruption resulting from man-made and natural disasters.

Some key findings from this report include:

  • McKesson, AmerisourceBergen and Cardinal Health Inc, known as the Big Three', account for between 90-95% of revenue within the US pharmaceutical wholesale sector.
  • The Big Three' have been responsible for over 100 buyouts since 1980, at least 57 of which have occurred over the past decade.
  • It is estimated that US chain drug stores currently account for 41% of all prescription sales, with the dominant players being Walgreens and CVS Caremark.
  • A change from wholesale to direct distribution in the US is unlikely. A US wide direct distribution model would cost the pharmaceutical industry $47.9bn to operate. This would be 15.5% increase on current distribution costs.

Companies Mentioned:

  • American Pharmacists Association
  • AmeriSource
  • AmerisourceBergen
  • Bergen Brunswig
  • Boehringer Ingelheim
  • Cardinal Health
  • Centers for Medicare and Medicaid Services
  • CVS Caremark
  • Food and Drug Administration (FDA)
  • GlaxoSmithKline
  • Informed Decisions, LLC
  • K-Mart
  • Lewin Group
  • McKesson Distribution Solutions
  • Nadro
  • National Association of Chain Drug Stores
  • National Community Pharmacists Association
  • Pfizer
  • Pharmaceutical Research and Manufacturers of America
  • RxHub
  • RxUSA
  • Sanofi-Aventis
  • SureScripts
  • Verispan
  • Walgreens
  • Wal-Mart Target
  • Wegmans
  • Wyeth

For more information visit http://www.researchandmarkets.com/research/ab0ae1/pharmaceutical_dis

Source: Spectra Intelligence



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:   Europe  Ireland

INDUSTRY KEYWORDS:   Health  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

A suspected cancer-causing impurity that has been found in some blood pressure medicines has now shown up in Zantac and some OTC antacids.

Roche is steamrolling with Ocrevus, and to maintain that lead, its touting long-term data that show the earlier it’s given, the better patients do.

New data shows a significant reduction in relapse rates in patients taking Novartis' repurposed cancer drug ofatumumab.